ADVA
30.4.2020 09:02:05 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso has deployed its ConnectGuard™ Cloud encryption solution for robust software-based network protection. By leveraging the industry-first cloud-native technology, the IT service provider is ensuring end-to-end security for its virtual private network (VPN). The cost-effective and low-latency solution is now safeguarding connectivity between dacoso’s data centers in Germany, Austria and Switzerland, as well as its virtual cloud services. The deployment improves dacoso’s bandwidth efficiency while complying with all relevant industry standards. Also, by moving to a cloud-native security solution, dacoso’s mission-critical network benefits from enhanced flexibility and cost-efficiency.
“By deploying ADVA’s ConnectGuard™ Cloud technology, we’re harnessing virtualized encryption that’s flexible, scalable and doesn’t come with a heavy bandwidth penalty. The solution ensures rigorous data protection for both our branches and our cloud locations. And, because it works without large additional data ballast, it also improves network utilization and reduces cost-per-encrypted-bit,” said Karsten Geise, head of business and product development, dacoso. “Now our cloud network meets all regulatory requirements, such as GDPR, while being simpler and more efficient. Removing the need for hardware appliances also frees up valuable rack space and means we can easily shop around for new innovation in the future rather than being constrained by single-vendor lock-in.”
dacoso provides managed services for businesses that rely on the highest levels of security, including virtual environments. As hardware-based encryption isn’t possible in cloud provider data centers, the software-based protection that ConnectGuard™ Cloud offers is vital. Based on ADVA’s industry-leading Ensemble Connector virtualization platform, the solution delivers a host of benefits. These include end-to-end encryption at Layer 2, 3 and 4, along with improved latency and throughput performance compared to IPSec. With its zero-touch provisioning and automated key management, ADVA’s unique cloud-native technology also significantly simplifies operations for dacoso’s team. Complexity is further reduced by automated key distribution and management, centrally orchestrated by the ADVA Ensemble Controller management solution.
“dacoso now has all the advantages of highly efficient and extremely rigorous encryption, delivered entirely through software. That means ultra-low latency protection at Layers 2, 3 and 4, as well as unrivaled advantages in terms of scale and ease of use,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “ConnectGuard™ Cloud really is the ultimate solution for site-to-site and site-to-cloud encrypted VPNs. It’s also the perfect fit for dacoso’s needs. With transport-layer independent security, they can rely on comprehensive protection that won’t affect the performance of the services it provides. What’s more, as part of our Ensemble portfolio of open NFV solutions, ConnectGuard™ Cloud unshackles dacoso from vendor lock-in and offers freedom to mix and match new technologies in the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Cyber Security and Virtual Networking. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso services comprise, among other, optical data links encrypted to satisfy BSI, a certified Security Operation Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen, Frankfurt a.M., with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
